DYN — Dyne Therapeutics
Median target
$36
calls from the last 12 months
Implied return
+99.4%
median target vs. price
Coverage
15 analysts · 16 calls
updated in the last 12 months
Consensus
13/1/1+12 net
Buy / Hold / Sell
Which analysts are behind DYN's consensus?
See every current rating, price target and the analysts' track records for Dyne Therapeutics — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 15 analysts with calls on DYN updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
DYN elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-10-02 | Insiders | Posner Brian SDirector | Insider purchase | 2.5K sh @ $16.00 | $40K |
| 2026-09-08 | Insiders | Cox JohnDirector,Officer | Insider sale | 5.7K sh @ $18.88 · planned trade | $107K |
| 2026-09-08 | Insiders | Kerr DouglasOfficer | Insider sale | 1.3K sh @ $18.88 · planned trade | $24K |
| 2026-09-08 | Insiders | Friedl-Naderer JohannaOfficer | Insider sale | 185 sh @ $18.88 · planned trade | $3K |
More: insider activity · executive branch · trending